Company Announcement, Helsinki, 3 July 2026 at 9 AM (EEST)
Nexstim Receives NBS 6 Therapy System Order from New Customer in the United States
Nexstim Plc (”Nexstim” or ”Company”) has received an order for an NBS 6 from a new customer in the United States. The system will be used for therapeutic applications.
The order comprises an NBS 6 Therapy Base Unit, cleared by the U.S. Food and Drug Administration (FDA) for the treatment of Major Depressive Disorder (MDD) in adults and adolescents and as an adjunct for the treatment of Obsessive Compulsive Disorder (OCD). The delivered configuration includes Nexstim’s non-disposable solution with re-usable head trackers, supporting increased sustainability, clinical efficiency and cost-effectiveness.
The NBS 6 leverages Nexstim’s proprietary SmartFocus® nTMS technology, which enables accurate and precise targeting of the stimulation location by visualizing the induced electric field in the brain. This supports personalized treatment delivery and reproducibility across therapy sessions, independent of device operator.
Mikko Karvinen, CEO of Nexstim, comments: “We are pleased to welcome this new customer in the United States and to support their efforts in providing advanced neuromodulation therapies to the patients in their community. The United States remains a key market for Nexstim’s therapy business, with a growing number of clinics adopting navigated TMS to enhance treatment outcomes for patients.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of Major Depressive Disorder (MDD) in adult and adolescent patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode, and as an adjunct for the treatment of adult patients suffering from Obsessive Compulsive Disorder (OCD). In Europe, the NBS System 6 is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com.